Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Kanellias, Nikolaos, Christoulas, Dimitrios, Kastritis, Efstathios, Dimopoulos, Meletios A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656921/
https://www.ncbi.nlm.nih.gov/pubmed/23690693
http://dx.doi.org/10.2147/OTT.S34498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656921/
https://www.ncbi.nlm.nih.gov/pubmed/23690693
http://dx.doi.org/10.2147/OTT.S34498

Ejemplares similares